Bionaut Labs, a Los Angeles, CA-based company that uses microscale robots to improve the treatment of central nervous system (CNS) diseases and disorders, raised $43M in Series B funding.
The round was led by Khosla Ventures with participation from Deep Insight, OurCrowd, PSPRS, Sixty Degree Capital, Dolby Family Ventures, GISEV Family Ventures, What if Ventures, Tintah Grace, Gaingels, Upfront Ventures, BOLD Capital Partners, Revolution VC, and Compound.
The company intends to use the funds to advance clinical development of its lead programs against malignant glioma brain tumors and Dandy-Walker Syndrome (a rare pediatric neurological disorder).
Co-founded by two robotics entrepreneurs, Michael Shpigelmacher and Aviad Maizels, Bionaut Labs is a biotech company focused on micro-technology with the deployment of microscale robots, to remove the barriers of localized treatment and detection of diseases. Through magnetic propulsion, Bionauts™ can navigate the human body to deliver drugs locally, generating efficacy and avoiding side effects and toxicity from systemically delivered drugs. By reaching the midbrain safely through novel routes, Bionaut Labs aims to develop solutions to treat the most debilitating conditions including Parkinson’s disease and Huntington’s disease, malignant glioma and hydrocephalus.
Bionaut Labs also has additional R&D sites in Israel and at the Max Planck Institute in Germany.
FinSMEs
28/11/2022